Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 21, 2019. The document serves as an LSE Announcement regarding positive clinical data from the DREAMM-1 study of GSK2857916, an investigational anti-BCMA antibody-drug conjugate for patients with relapsed/refractory multiple myeloma.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain financial statements or performance metrics.
Material Changes and Clinical Results
The filing details updated results from the DREAMM-1 study following more than a year of follow-up compared to the 2017 interim analysis:
- Overall Response Rate (ORR): Remained at 60% for all patients receiving GSK2857916.
- Complete Response: Increased to 15% over the additional follow-up period.
- Median Progression-Free Survival (PFS): Increased from 7.9 months to 12 months (95% CI [3.1-Not Estimable]).
- Median Duration of Response: Final analysis showed 14.3 months (95% CI [10.6-NE]).
- Subgroup Analysis (35 patients in Part 2):
- Patients not previously treated with daratumumab: ORR of 71% and mPFS of 15.7 months.
- Patients previously treated with daratumumab: ORR of 38.5% and mPFS of 7.9 months.
Outlook, Risks, and Management Commentary
Management Commentary: Dr. Hal Barron, Chief Scientific Officer and President of R&D, described the data as "very encouraging," highlighting the durability and depth of response. GSK plans to have pivotal data to support regulatory filing by the end of 2019.
Safety Profile: No new safety signals were identified. Common adverse events included thrombocytopenia (63%), blurred vision (51%), and cough (40%), mostly mild or moderate. Grade 3 or 4 events were primarily thrombocytopenia (35%) and anemia (17%), deemed manageable.
Risks and Contingencies: GSK2857916 is not currently approved for use anywhere in the world. The drug is still in clinical development, and future success depends on the outcomes of ongoing and planned Phase III trials (DREAMM-3, DREAMM-7, DREAMM-8, DREAMM-9).
Investor Verification Checklist
- Verify the timeline for pivotal data submission and regulatory filing expected by the end of 2019.
- Monitor the status and enrollment of ongoing Phase III trials (DREAMM-3, DREAMM-7, DREAMM-8) to assess commercial potential.
- Review the safety data regarding thrombocytopenia and anemia in larger Phase III cohorts.
- Confirm the competitive landscape for anti-BCMA therapies and potential approval pathways in the US and EU.